Paolo Curatolo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9218080/publications.pdf

Version: 2024-02-01

318 papers	16,146 citations	18465 62 h-index	22147 113 g-index
329 all docs	329 docs citations	329 times ranked	13074 citing authors

#	Article	IF	Citations
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	1.0	1,185
2	Tuberous sclerosis. Lancet, The, 2008, 372, 657-668.	6.3	967
3	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	1.0	693
4	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2013, 381, 125-132.	6.3	687
5	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet, The, 2016, 388, 2153-2163.	6.3	554
6	Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurology, The, 2015, 14, 733-745.	4.9	437
7	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	1.0	230
8	Current role of melatonin in pediatric neurology: Clinical recommendations. European Journal of Paediatric Neurology, 2015, 19, 122-133.	0.7	219
9	Comorbidity of ADHD and Dyslexia. Developmental Neuropsychology, 2010, 35, 475-493.	1.0	197
10	Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain and Development, 2009, 31, 104-113.	0.6	191
11	Tuberous sclerosis complex: a review of neurological aspects. European Journal of Paediatric Neurology, 2002, 6, 15-23.	0.7	186
12	Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations. European Journal of Paediatric Neurology, 2012, 16, 582-586.	0.7	178
13	Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. European Journal of Paediatric Neurology, 2010, 14, 146-149.	0.7	176
14	Preterm birth and neurodevelopmental outcome: a review. Child's Nervous System, 2010, 26, 1139-1149.	0.6	168
15	TuberOus SClerosis registry to increase disease Awareness (TOSCA) â€“ baseline data on 2093 patients. Orphanet Journal of Rare Diseases, 2017, 12, 2.	1.2	166
16	Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncology, The, 2014, 15, 1513-1520.	5.1	152
17	Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. European Journal of Paediatric Neurology, 2018, 22, 738-748.	0.7	151
18	Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS ONE, 2016, 11, e0158476.	1.1	146

#	Article	IF	Citations
19	Attention and executive functions profile in drug naive ADHD subtypes. Brain and Development, 2007, 29, 400-408.	0.6	144
20	Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the <scp>EPISTOP</scp> Trial. Annals of Neurology, 2021, 89, 304-314.	2.8	137
21	Clinical, Morphological, and Biochemical Correlates of Head Circumference in Autism. Biological Psychiatry, 2007, 62, 1038-1047.	0.7	131
22	Epilepsy in tuberous sclerosis complex: Findings from the <scp>TOSCA</scp> Study. Epilepsia Open, 2019, 4, 73-84.	1.3	125
23	Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy and Behavior, 2011, 22, 735-739.	0.9	120
24	Autism in tuberous sclerosis: evoked potential evidence for a deficit in auditory sensory processing. Clinical Neurophysiology, 1999, 110, 1825-1830.	0.7	118
25	The neurobiological basis of ADHD. Italian Journal of Pediatrics, 2010, 36, 79.	1.0	117
26	Mechanistic Target of Rapamycin (mTOR) in Tuberous Sclerosis Complex-Associated Epilepsy. Pediatric Neurology, 2015, 52, 281-289.	1.0	117
27	Sleep abnormalities in mentally retarded autistic subjects: Down's syndrome with mental retardation and normal subjects. Brain and Development, 1999, 21, 548-553.	0.6	115
28	Urinary p-cresol is elevated in small children with severe autism spectrum disorder. Biomarkers, 2011, 16, 252-260.	0.9	115
29	Autism in tuberous sclerosis. European Journal of Paediatric Neurology, 2004, 8, 327-332.	0.7	113
30	Genetics and Molecular Biology of Tuberous Sclerosis Complex. Current Genomics, 2008, 9, 475-487.	0.7	107
31	mTOR Inhibitors in Tuberous Sclerosis Complex. Current Neuropharmacology, 2012, 10, 404-415.	1.4	106
32	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet Journal of Rare Diseases, 2018, 13, 157.	1.2	106
33	Attention deficit hyperactivity disorder in children with epilepsy. Brain and Development, 2010, 32, 10-16.	0.6	104
34	Infantile spasms in tuberous sclerosis complex. Brain and Development, 2001, 23, 502-507.	0.6	103
35	Autism and Metabolic Diseases. Journal of Child Neurology, 2008, 23, 307-314.	0.7	103
36	The neurobiology of attention deficit/hyperactivity disorder. European Journal of Paediatric Neurology, 2009, 13, 299-304.	0.7	102

#	Article	IF	Citations
37	Toxocara Infection and Epilepsy in Children: A Caseâ€Control Study. Epilepsia, 1990, 31, 33-36.	2.6	100
38	The Relationship between Sleep Problems, Neurobiological Alterations, Core Symptoms of Autism Spectrum Disorder, and Psychiatric Comorbidities. Journal of Clinical Medicine, 2018, 7, 102.	1.0	98
39	Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain and Development, 2017, 39, 464-469.	0.6	97
40	Genotype/Phenotype Correlations in Tuberous Sclerosis Complex. Seminars in Pediatric Neurology, 2015, 22, 259-273.	1.0	96
41	Sleep Architecture and NREM Alterations in Children and Adolescents with Asperger Syndrome. Sleep, 2007, 30, 1577-1585.	0.6	92
42	Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. European Journal of Paediatric Neurology, 2013, 17, 348-352.	0.7	92
43	Autistic Symptoms in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 78.	1.3	86
44	Principal pathogenetic components and biological endophenotypes in autism spectrum disorders. Autism Research, 2010, 3, 237-252.	2.1	85
45	Everolimus for treatment-refractory seizures in TSC. Neurology: Clinical Practice, 2018, 8, 412-420.	0.8	85
46	The relationship between sleep and epilepsy: the effect on cognitive functioning in children. Developmental Medicine and Child Neurology, 2010, 52, 805-810.	1.1	83
47	Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment. Journal of Child Neurology, 2005, 20, 318-325.	0.7	82
48	Disruption of mTOR and MAPK pathways correlates with severity in idiopathic autism. Translational Psychiatry, 2019, 9, 50.	2.4	81
49	Developmental and epileptic encephalopathies: what we do and do not know. Brain, 2021, 144, 32-43.	3.7	81
50	Long term clinical course of Tourette syndrome. Brain and Development, 2012, 34, 667-673.	0.6	79
51	Syndromic autism: causes and pathogenetic pathways. World Journal of Pediatrics, 2009, 5, 169-176.	0.8	77
52	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child and Adolescent Health, 2018, 2, 495-504.	2.7	77
53	Autism Spectrum Disorders in Tuberous Sclerosis: Pathogenetic Pathways and Implications for Treatment. Journal of Child Neurology, 2010, 25, 873-880.	0.7	76
54	Comorbidity between ADHD and anxiety disorders across the lifespan. International Journal of Psychiatry in Clinical Practice, 2019, 23, 238-244.	1.2	73

#	Article	IF	Citations
55	Sleep disorders in tuberous sclerosis: a polysomnographic study. Brain and Development, 1995, 17, 52-56.	0.6	71
56	Chikungunya and the nervous system: what we do and do not know. Reviews in Medical Virology, 2009, 19, 121-129.	3.9	71
57	Current Advances in Childhood Absence Epilepsy. Pediatric Neurology, 2014, 50, 205-212.	1.0	71
58	A clinical update on tuberous sclerosis complexâ€ associated neuropsychiatric disorders (TAND). American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 309-320.	0.7	71
59	Risk and Protective Environmental Factors Associated with Autism Spectrum Disorder: Evidence-Based Principles and Recommendations. Journal of Clinical Medicine, 2019, 8, 217.	1.0	71
60	Vigabatrin for tuberous sclerosis complex. Brain and Development, 2001, 23, 649-653.	0.6	69
61	Disentangling the effects of Tourette syndrome and attention deficit hyperactivity disorder on cognitive and behavioral phenotypes. Brain and Development, 2007, 29, 413-420.	0.6	69
62	Attention and executive functions profile in childhood absence epilepsy. Brain and Development, 2012, 34, 812-817.	0.6	69
63	mTOR dysregulation and tuberous sclerosis-related epilepsy. Expert Review of Neurotherapeutics, 2018, 18, 185-201.	1.4	68
64	Epilepsy associated with autism and attention deficit hyperactivity disorder: Is there a genetic link?. Brain and Development, 2014, 36, 185-193.	0.6	67
65	The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs, 2016, 76, 551-565.	4.9	66
66	Tourette Syndrome and comorbid ADHD: Current pharmacological treatment options. European Journal of Paediatric Neurology, 2013, 17, 421-428.	0.7	64
67	mTOR Inhibitors in Tuberous Sclerosis Complex. Current Neuropharmacology, 2012, 10, 404-415.	1.4	64
68	Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics, 2001, 3, 111-113.	0.7	62
69	Epilepsy surgery for tuberous sclerosis. Pediatric Neurology, 2004, 31, 239-247.	1.0	62
70	TOSCA â€“ first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet Journal of Rare Diseases, 2014, 9, 182.	1.2	62
71	Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology, 2004, 63, 373-375.	1.5	60
72	Lacosamide in pediatric and adult patients: Comparison of efficacy and safety. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 210-216.	0.9	60

#	Article	IF	Citations
73	Increased Brain Apparent Diffusion Coefficient in Tuberous Sclerosis. Radiology, 2004, 232, 461-465.	3.6	58
74	Efficacy of intensive versus nonintensive physiotherapy in children with cerebral palsy: a meta-analysis. International Journal of Rehabilitation Research, 2010, 33, 165-171.	0.7	55
75	HERVs Expression in Autism Spectrum Disorders. PLoS ONE, 2012, 7, e48831.	1.1	55
76	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrology Dialysis Transplantation, 2019, 34, 502-508.	0.4	55
77	Sleep Spindle Activity Is Correlated With Reading Abilities in Developmental Dyslexia. Sleep, 2009, 32, 1333-1340.	0.6	54
78	The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Child's Nervous System, 2011, 27, 1203-1210.	0.6	54
79	Cluster Analysis of Autistic Patients Based on Principal Pathogenetic Components. Autism Research, 2012, 5, 137-147.	2.1	54
80	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European Journal of Paediatric Neurology, 2018, 22, 1066-1073.	0.7	54
81	Rufinamide in children and adults with Lennoxâ€“Gastaut syndrome: First Italian multicenter experience. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 587-591.	0.9	52
82	Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome. Human Genetics, 2015, 134, 181-190.	1.8	52
83	The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure: the Journal of the British Epilepsy Association, 2018, 63, 17-25.	0.9	52
84	Levetiracetam in absence epilepsy. Developmental Medicine and Child Neurology, 2008, 50, 850-853.	1.1	51
85	ADHD and genetic syndromes. Brain and Development, 2011, 33, 456-461.	0.6	51
86	TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study. Genetics in Medicine, 2020, 22, 1489-1497.	1.1	51
87	Hypohidrosis During Topiramate Treatment:A Rare and Reversible Side Effect. Pediatric Neurology, 2006, 34, 392-394.	1.0	50
88	Levetiracetam in Childhood Epilepsy. Paediatric Drugs, 2010, 12, 177-186.	1.3	50
89	Vagus Nerve Stimulation for Refractory Epilepsy in Tuberous Sclerosis. Pediatric Neurology, 2010, 43, 29-34.	1.0	49
90	Pharmacotherapy of autism spectrum disorders. Brain and Development, 2013, 35, 119-127.	0.6	49

#	Article	IF	Citations
91	Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC. European Journal of Paediatric Neurology, 2016, 20, 203-211.	0.7	49
92	Current role of vigabatrin in infantile spasms. European Journal of Paediatric Neurology, 2007, 11, 331-336.	0.7	48
93	Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Child's Nervous System, 2010, 26, 1495-1504.	0.6	48
94	Current management for epilepsy in tuberous sclerosis complex. Current Opinion in Neurology, 2006, 19, 119-123.	1.8	47
95	Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. European Neuropsychopharmacology, 2009, 19, 822-834.	0.3	47
96	Tourette Syndrome and Comorbid Conditions. Journal of Child Neurology, 2014, 29, 1383-1389.	0.7	47
97	Human endogenous retroviruses and ADHD. World Journal of Biological Psychiatry, 2014, 15, 499-504.	1.3	47
98	Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment. Scientific Reports, 2017, 7, 8089.	1.6	47
99	Is mTOR inhibition a systemic treatment for tuberous sclerosis?. Italian Journal of Pediatrics, 2013, 39, 57.	1.0	46
100	Tuberous sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 129-151.	1.0	45
101	Levetiracetam in juvenile myoclonic epilepsy: longâ€term efficacy in newly diagnosed adolescents. Developmental Medicine and Child Neurology, 2008, 50, 29-32.	1.1	45
102	Attention-Deficit Hyperactivity Disorder (ADHD) and Tuberous Sclerosis Complex. Journal of Child Neurology, 2009, 24, 1282-1287.	0.7	45
103	Family-based association study of ITGB3 in autism spectrum disorder and its endophenotypes. European Journal of Human Genetics, 2011, 19, 353-359.	1.4	45
104	Benign childhood epilepsy with centrotemporal spikes and the multicomponent model of attention: A matched control study. Epilepsy and Behavior, 2010, 19, 69-77.	0.9	44
105	Neurological manifestations of tuberous sclerosis complex. Child's Nervous System, 1996, 12, 515-21.	0.6	43
106	Topical Review : Neurologic Aspects of Adenylosuccinate Lyase Deficiency. Journal of Child Neurology, 2001, 16, 301-308.	0.7	43
107	Genetic Polymorphisms and Idiopathic Generalized Epilepsies. Pediatric Neurology, 2007, 37, 157-164.	1.0	43
108	mTOR inhibitors as a new therapeutic option for epilepsy. Expert Review of Neurotherapeutics, 2013, 13, 627-638.	1.4	43

#	Article	IF	Citations
109	Use of the DISCERN tool for evaluating web searches in childhood epilepsy. Epilepsy and Behavior, 2014, 41, 119-121.	0.9	42
110	Early Clinical Predictors of Autism Spectrum Disorder in Infants with Tuberous Sclerosis Complex: Results from the EPISTOP Study. Journal of Clinical Medicine, 2019, 8, 788.	1.0	42
111	The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity. Clinical Drug Investigation, 2018, 38, 1-8.	1.1	41
112	Potential for diagnosis versus therapy monitoring of attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype and auto-immunity. European Child and Adolescent Psychiatry, 2018, 27, 241-252.	2.8	41
113	Clinical features of psychogenic non-epileptic seizures in prepubertal and pubertal patients with idiopathic epilepsy. Neurological Sciences, 2009, 30, 319-323.	0.9	38
114	Detection of auto-antibodies to DAT in the serum: Interactions with DAT genotype and psycho-stimulant therapy for ADHD. Journal of Neuroimmunology, 2015, 278, 212-222.	1.1	37
115	Prenatal and Perinatal Determinants of Neonatal Seizures Occurring in the First Week of Life. Journal of Child Neurology, 2001, 16, 651-656.	0.7	36
116	Attention impairment in childhood absence epilepsy: An impulsivity problem?. Epilepsy and Behavior, 2013, 27, 337-341.	0.9	36
117	Are caesarean sections, induced labor and oxytocin regulation linked to Autism Spectrum Disorders?. Medical Hypotheses, 2014, 82, 713-718.	0.8	36
118	Autism and Epilepsy in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2020, 11, 639.	1.1	36
119	Current concepts on epilepsy management in tuberous sclerosis complex. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 299-308.	0.7	35
120	Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. Drugs, 2021, 81, 101-123.	4.9	35
121	Frontal Lobe Epilepsy Associated With Tuberous Sclerosis: Electroencephalographic-Magnetic Resonance Image Fusioning. Journal of Child Neurology, 1998, 13, 33-38.	0.7	34
122	Management of epilepsy in tuberous sclerosis complex. Expert Review of Neurotherapeutics, 2008, 8, 457-467.	1.4	34
123	Decreased serum arylesterase activity in autism spectrum disorders. Psychiatry Research, 2010, 180, 105-113.	1.7	33
124	Diagnostic Yield of a Targeted Next-Generation Sequencing Gene Panel for Pediatric-Onset Movement Disorders: A 3-Year Cohort Study. Frontiers in Genetics, 2019, 10, 1026.	1.1	33
125	Changes in cerebral blood flow velocities during childhood absence seizures. Pediatric Neurology, 1998, 18, 132-135.	1.0	32
126	Current role of rufinamide in the treatment of childhood epilepsy: Literature review and treatment guidelines. European Journal of Paediatric Neurology, 2014, 18, 685-690.	0.7	32

#	Article	IF	Citations
127	Children With Autism Spectrum Disorder and Their Mothers Share Abnormal Expression of Selected Endogenous Retroviruses Families and Cytokines. Frontiers in Immunology, 2019, 10, 2244.	2.2	32
128	Headache and attention deficit and hyperactivity disorder in children: Common condition with complex relation and disabling consequences. Epilepsy and Behavior, 2014, 32, 72-75.	0.9	31
129	Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. CNS Drugs, 2015, 29, 865-877.	2.7	31
130	Gelastic Epilepsy and True Precocious Puberty due to Hypothalamic Hamartoma. Developmental Medicine and Child Neurology, 1984, 26, 509-514.	1.1	30
131	Neurologic Aspects of Adenylosuccinate Lyase Deficiency. Journal of Child Neurology, 2001, 16, 301.	0.7	30
132	Pharmacologic treatment of autism. Journal of Child Neurology, 2004, 19, 155-64.	0.7	30
133	Motor cortical inhibition in ADHD: modulation of the transcranial magnetic stimulation-evoked N100 in a response control task. Journal of Neural Transmission, 2014, 121, 315-325.	1.4	29
134	Reduction in Retinal Nerve Fiber Layer Thickness in Young Adults with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders, 2014, 44, 873-882.	1.7	29
135	Seizures in Chiari I Malformation: A Clinical and Electroencephalographic Study. Journal of Child Neurology, 1999, 14, 446-450.	0.7	28
136	Brain damage in preterm infants: etiological pathways. Annali Dell'Istituto Superiore Di Sanita, 2005, 41, 229-37.	0.2	28
137	Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS ONE, 2018, 13, e0201005.	1.1	27
138	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Frontiers in Neurology, 2020, 11, 972.	1.1	27
139	Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opinion on Drug Safety, 2018, 17, 1015-1028.	1.0	26
140	The Impact of COVID-19 on the Adaptive Functioning, Behavioral Problems, and Repetitive Behaviors of Italian Children with Autism Spectrum Disorder: An Observational Study. Children, 2021, 8, 96.	0.6	26
141	Vitamin D Deficiency and Autism Spectrum Disorder. Current Pharmaceutical Design, 2020, 26, 2460-2474.	0.9	26
142	Deletion 2q37: An Identifiable Clinical Syndrome With Mental Retardation and Autism. Journal of Child Neurology, 2008, 23, 802-806.	0.7	25
143	Infantile Spasms and the CHARGE Association. Developmental Medicine and Child Neurology, 2008, 25, 367-369.	1.1	25
144	Autism and Infantile Spasms in Children with Tuberous Sclerosis. Developmental Medicine and Child Neurology, 1987, 29, 551-551.	1.1	25

#	Article	IF	Citations
145	Slow EEG Amplitude Oscillations During NREM Sleep and Reading Disabilities in Children With Dyslexia. Developmental Neuropsychology, 2009, 34, 539-551.	1.0	25
146	Zonisamide in children and young adults with refractory epilepsy: An open label, multicenter Italian study. Epilepsy Research, 2009, 83, 112-116.	0.8	25
147	Electroclinical Features and Long-Term Outcome of Cryptogenic Epilepsy in Children with Down Syndrome. Journal of Pediatrics, 2013, 163, 1754-1758.	0.9	25
148	Current role of perampanel in pediatric epilepsy. Italian Journal of Pediatrics, 2017, 43, 51.	1.0	25
149	Magnetic source imaging and reactivity to rhythmical stimulation in tuberous sclerosis. Brain and Development, 1998, 20, 512-518.	0.6	24
150	RISK FACTORS FOR THE COOCCURRENCE OF PARTIAL EPILEPSY, CEREBRAL PALSY AND MENTAL RETARDATION. Developmental Medicine and Child Neurology, 1995, 37, 776-782.	1.1	24
151	Recommendations for early diagnosis and intervention in autism spectrum disorders: An Italianâ€“Israeli consensus conference. European Journal of Paediatric Neurology, 2014, 18, 107-118.	0.7	24
152	Tourette syndrome and comorbid ADHD: causes and consequences. European Journal of Pediatrics, 2015, 174, 279-288.	1.3	24
153	Childhood Rapid-Onset Ataxia: Expanding the Phenotypic Spectrum of ATP1A3 Mutations. Cerebellum, 2018, 17, 489-493.	1.4	24
154	Rufinamide for refractory focal seizures: An open-label, multicenter European study. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 33-36.	0.9	23
155	Epilepsy in patients with Cornelia de Lange syndrome: A clinical series. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 356-359.	0.9	23
156	ATP1A3 -related epileptic encephalopathy responding to ketogenic diet. Brain and Development, 2018, 40, 433-438.	0.6	23
157	Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?. Annals of Clinical and Translational Neurology, 2020, 7, 1371-1381.	1.7	23
158	Long term outcome in children affected by absence epilepsy with onset before the age of three years. Epilepsy and Behavior, 2011, 20, 366-369.	0.9	22
159	Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex â€“ Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. Frontiers in Pharmacology, 2018, 9, 964.	1.6	22
160	Autism Spectrum Disorder: Why Do We Know So Little?. Frontiers in Neurology, 2018, 9, 670.	1.1	22
161	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. Frontiers in Neurology, 2019, 10, 705.	1.1	22
162	A novel KCTD17 mutation is associated with childhood early-onset hyperkinetic movement disorder. Parkinsonism and Related Disorders, 2019, 61, 4-6.	1.1	22

#	Article	IF	Citations
163	The epilepsyâ€“autism spectrum disorder phenotype in the era of molecular genetics and precision therapy. Epilepsia, 2022, 63, 6-21.	2.6	22
164	White matter disruption is associated with persistent seizures in tuberous sclerosis complex. Epilepsy and Behavior, 2016, 60, 63-67.	0.9	21
165	Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1054-1064.	0.9	21
166	Neurologic Aspects of 49,XXXXY Syndrome. Journal of Child Neurology, 2003, 18, 501-504.	0.7	20
167	Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions. CNS Drugs, 2009, 23, 739-753.	2.7	20
168	Hypnic headache in children. Cephalalgia, 2011, 31, 1673-1676.	1.8	20
169	Two epileptic syndromes, one brain: Childhood absence epilepsy and benign childhood epilepsy with centrotemporal spikes. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 70-74.	0.9	20
170	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. Frontiers in Neurology, 2020, 11, 904.	1.1	20
171	Efficacy of Rufinamide in Drug-Resistant Epilepsy: A Meta-analysis. Pediatric Neurology, 2011, 44, 347-349.	1.0	19
172	Promoting Shared Decision Making to strengthen outcome of young children with Autism Spectrum Disorders: The role of staff competence. Research in Developmental Disabilities, 2015, 38, 48-63.	1.2	19
173	Prediction of Neurodevelopment in Infants With Tuberous Sclerosis Complex Using Early EEG Characteristics. Frontiers in Neurology, 2020, 11, 582891.	1.1	19
174	Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes. Epilepsia, 2021, 62, 1208-1219.	2.6	19
175	Exanthematic diseases during pregnancy and attention-deficit/hyperactivity disorder (ADHD). European Journal of Paediatric Neurology, 2005, 9, 363-365.	0.7	18
176	Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: Significant clinical improvement during tamoxifen treatment. Journal of Hepatology, 2008, 48, 1026-1029.	1.8	18
177	Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. Epilepsy Research, 2014, 108, 542-546.	0.8	18
178	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. Frontiers in Neurology, 2019, 10, 821.	1.1	18
179	Refractory absence seizures: An Italian multicenter retrospective study. European Journal of Paediatric Neurology, 2015, 19, 660-664.	0.7	17
180	Surgery for drugâ€resistant tuberous sclerosis complexâ€associated epilepsy: who, when, and what. Epileptic Disorders, 2021, 23, 53-73.	0.7	17

#	Article	IF	Citations
181	The neurology of attention deficit/hyperactivity disorder. Brain and Development, 2005, 27, 541-543.	0.6	16
182	Deletion 2p25.2: A cryptic chromosome abnormality in a patient with autism and mental retardation detected using aCGH. European Journal of Medical Genetics, 2009, 52, 67-70.	0.7	16
183	De novo mosaic ring chromosome 18 in a child with mental retardation, epilepsy and immunological problems. European Journal of Medical Genetics, 2011, 54, 329-332.	0.7	16
184	Seizures Induced by Desloratadine, A Second-Generation Antihistamine: Clinical Observations. Neuropediatrics, 2013, 44, 222-224.	0.3	16
185	Pancreatic Neuroendocrine Tumor in a Child with a Tuberous Sclerosis Complex 2 (TSC2) Mutation. Endocrine Practice, 2013, 19, e124-e128.	1.1	16
186	Planning Deficit in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2014, 29, 1320-1326.	0.7	16
187	Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex. Seminars in Pediatric Neurology, 2015, 22, 282-294.	1.0	16
188	Comorbidity of ADHD and High-functioning Autism. Journal of Psychiatric Practice, 2016, 22, 22-30.	0.3	16
189	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. Journal of Neurodevelopmental Disorders, 2020, 12, 24.	1.5	16
190	Lack of Infection with XMRV or Other MLV-Related Viruses in Blood, Post-Mortem Brains and Paternal Gametes of Autistic Individuals. PLoS ONE, 2011, 6, e16609.	1.1	16
191	Adjunctive everolimus therapy for tuberous sclerosis complexâ€associated refractory seizures: Results from the postextension phase of EXISTâ€3. Epilepsia, 2021, 62, 3029-3041.	2.6	16
192	Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome. Brain and Development, 2010, 32, 425-427.	0.6	15
193	Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. Pediatric Neurology, 2017, 68, 59-63.	1.0	15
194	Sex Differences in Autism Spectrum Disorder: Repetitive Behaviors and Adaptive Functioning. Children, 2021, 8, 325.	0.6	15
195	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA). Orphanet Journal of Rare Diseases, 2021, 16, 301.	1.2	15
196	Differing Risk Factors for Cerebral Palsy in the Presence of Mental Retardation and Epilepsy. Journal of Child Neurology, 1999, 14, 151-155.	0.7	14
197	Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: The first Italian prospective study. Epilepsy Research, 2012, 102, 94-99.	0.8	14
198	Reflex myoclonic epilepsy in infancy: a critical review. Epileptic Disorders, 2013, 15, 114-122.	0.7	14

#	Article	IF	Citations
199	Effects of oral administration of common antioxidant supplements on the energy metabolism of red blood cells. Attenuation of oxidative stress-induced changes in Rett syndrome erythrocytes by CoQ10. Molecular and Cellular Biochemistry, 2020, 463, 101-113.	1.4	14
200	Developmental and epileptic encephalopathy due to SZT2 genomic variants: Emerging features of a syndromic condition. Epilepsy and Behavior, 2020, 108, 107097.	0.9	14
201	Tuberous Sclerosis: Diagnostic and Prognostic Problems. Pediatric Neurosurgery, 1985, 12, 123-125.	0.4	13
202	Epilepsy and electroencephalographic anomalies in chromosome 2 aberrations. Epilepsy Research, 2008, 79, 63-70.	0.8	13
203	The Decrease in Human Endogenous Retrovirus-H Activity Runs in Parallel with Improvement in ADHD Symptoms in Patients Undergoing Methylphenidate Therapy. International Journal of Molecular Sciences, 2018, 19, 3286.	1.8	13
204	Impact of Italian lockdown on Tourette's syndrome patients at the time of the <scp>COVID</scp>â€19 pandemic. Psychiatry and Clinical Neurosciences, 2020, 74, 610-612.	1.0	13
205	Treatment of infantile spasms: why do we know so little?. Expert Review of Neurotherapeutics, 2020, 20, 551-566.	1.4	13
206	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. Frontiers in Neurology, 2021, 12, 697467.	1.1	13
207	Interstitial deletion of a proximal 3p: A clinically recognisable syndrome. Brain and Development, 2007, 29, 312-316.	0.6	12
208	Late-Onset Epileptic Spasms in Children With Pallister-Killian Syndrome: A Report of Two New Cases and Review of the Electroclinical Aspects. Journal of Child Neurology, 2010, 25, 238-245.	0.7	12
209	Neurological soft signs are associated with attentional dysfunction in children with attention deficit hyperactivity disorder. Cognitive Neuropsychiatry, 2016, 21, 475-493.	0.7	12
210	Effectiveness of community-based treatment on clinical outcome in children with autism spectrum disorders: An Italian prospective study. Developmental Neurorehabilitation, 2016, 19, 1-9.	0.5	12
211	OPTICAL COHERENCE TOMOGRAPHY AND INFRARED IMAGES OF ASTROCYTIC HAMARTOMAS NOT REVEALED BY FUNDUSCOPY IN TUBEROUS SCLEROSIS COMPLEX. Retina, 2017, 37, 1383-1392.	1.0	12
212	Intractable epilepsy in tuberous sclerosis: is the tuber removal not enough?. Developmental Medicine and Child Neurology, 2010, 52, 987-987.	1.1	11
213	Autism spectrum disorders associated with chromosomal abnormalities. Research in Autism Spectrum Disorders, 2010, 4, 319-327.	0.8	11
214	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. Frontiers in Neurology, 2019, 10, 1144.	1.1	11
215	Two-loci ADA haplotypes in autistic disorder. American Journal of Medical Genetics Part A, 2002, 108, 339-340.	2.4	10
216	Association study of autistic disorder and chromosome 16p. American Journal of Medical Genetics Part A, 2003, 119A, 242-246.	2.4	10

#	Article	IF	Citations
217	The role of â^'850 tumor necrosis factor-Î± and apolipoprotein E genetic polymorphism in patients with Down's syndrome-related dementia. Neuroscience Letters, 2003, 352, 29-32.	1.0	10
218	The International Child Neurology Association: Personal View. Journal of Child Neurology, 2003, 18, 786-794.	0.7	10
219	Long-term outcome of epilepsy in patients with Praderâ€“Willi syndrome. Journal of Neurology, 2015, 262, 116-123.	1.8	10
220	Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway. Epilepsy and Behavior, 2022, 131, 107713.	0.9	10
221	TuberOus SClerosis registry to increase disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2021, 12, 630378.	1.1	10
222	Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report. Child's Nervous System, 2012, 28, 939-941.	0.6	9
223	Synapses as Therapeutic Targets for Autism Spectrum Disorders: An International Symposium Held in Pavia on July 4th, 2014. Frontiers in Cellular Neuroscience, 2014, 8, 309.	1.8	9
224	Role of ADHD symptoms as a contributing factor to obesity in patients with MC4R mutations. Medical Hypotheses, 2015, 84, 4-7.	0.8	9
225	Everolimus for Retinal Astrocytic Hamartomas in Tuberous Sclerosis Complex. Ophthalmology Retina, 2018, 2, 257-260.	1.2	9
226	Symmetrical bithalamic hyperdensities in asphyxiated full-term newborns: An early indicator of status marmoratus. Brain and Development, 1988, 10, 57-59.	0.6	8
227	Neurologic Aspects of Microcephalic Osteodysplastic Primordial Dwarfism Type II. Pediatric Neurology, 2008, 38, 435-438.	1.0	8
228	Abnormal parieto-motor connectivity in Tuberous Sclerosis Complex. Epilepsy Research, 2009, 87, 102-105.	0.8	8
229	Attention-deficit hyperactivity disorder and binge eating disorder in a patient with 2q21.1â€“q22.2 deletion. Psychiatric Genetics, 2012, 22, 202-205.	0.6	8
230	Neuropsychiatric impairment in children with Continuous Spikes and Waves during slow Sleep: A longâ€term follow-up study. Epilepsy and Behavior, 2012, 25, 558-562.	0.9	8
231	Paediatric use of melatonin (Author reply to D. J. Kennaway). European Journal of Paediatric Neurology, 2015, 19, 491-493.	0.7	8
232	Neurological soft signs, but not theory of mind and emotion recognition deficit distinguished children with ADHD from healthy control. Psychiatry Research, 2017, 256, 96-101.	1.7	8
233	Clustering Analysis Supports the Detection of Biological Processes Related to Autism Spectrum Disorder. Genes, 2020, 11, 1476.	1.0	8
234	Event-Related Potentials in ADHD Associated With Tuberous Sclerosis Complex: A Possible Biomarker of Symptoms Severity?. Frontiers in Neurology, 2020, 11, 546.	1.1	8

#	Article	IF	Citations
235	Use of nutritional supplements based on melatonin, tryptophan and vitamin B6 (Melamil TriptoÂ®) in children with primary chronic headache, with or without sleep disorders: a pilot study. Minerva Pediatrica, 2020, 72, 30-36.	2.6	8
236	Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex. Neurology, 2022, 98, .	1.5	8
237	A neurocutaneous disorder with a severe course: Wyburn-Mason's syndrome. Journal of Child Neurology, 2004, 19, 908-11.	0.7	8
238	Association between presenilin-1 â˜48C/T polymorphism and Downâ€™s syndrome. Neuroscience Letters, 2004, 367, 88-91.	1.0	7
239	Does cesarean section prevent mortality and cerebral ultrasound abnormalities in preterm newborns?. Journal of Maternal-Fetal and Neonatal Medicine, 2007, 20, 151-159.	0.7	7
240	MRI Appearance of Sturge-Weber Syndrome in Tuberous Sclerosis Complex: Is the Neural Crest the Culprit?. Journal of Child Neurology, 2009, 24, 263-266.	0.7	7
241	MTHFR C677T and A1298C polymorphisms and cerebral stroke in two twin gestations. Child's Nervous System, 2011, 27, 665-669.	0.6	7
242	Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor. Pediatric Blood and Cancer, 2016, 63, 719-722.	0.8	7
243	The Relationship between Autism Spectrum Disorder and Tourette Syndrome in Childhood: An Overview of Shared Characteristics. Journal of Pediatric Neurology, 2017, 15, 115-122.	0.0	7
244	Impaired Motor Timing in Tourette Syndrome: Results From a Caseâ€“Control Study in Children. Frontiers in Neurology, 2020, 11, 552701.	1.1	7
245	Results of quantitative EEG analysis are associated with autism spectrum disorder and development abnormalities in infants with tuberous sclerosis complex. Biomedical Signal Processing and Control, 2021, 68, 102658.	3.5	7
246	Pharmacotherapy for Seizures in Tuberous Sclerosis Complex. CNS Drugs, 2021, 35, 965-983.	2.7	7
247	Tuberous sclerosis: genes, brain, and behaviour. Developmental Medicine and Child Neurology, 2006, 48, 404.	1.1	7
248	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. Frontiers in Neurology, 2020, 11, 603.	1.1	7
249	Anophthalmia-Waardenburg Syndrome With Expanding Phenotype: Does Neural Crest Play a Role?. Journal of Child Neurology, 2007, 22, 1252-1255.	0.7	6
250	Pharmacotherapy of idiopathic generalized epilepsies. Expert Opinion on Pharmacotherapy, 2009, 10, 5-17.	0.9	6
251	Impairment in Flexible Regulation of Speed and Accuracy in Children with ADHD. Journal of the International Neuropsychological Society, 2013, 19, 1016-1020.	1.2	6
252	Oxygen exchange and energy metabolism in erythrocytes of Rett syndrome and their relationships with respiratory alterations. Molecular and Cellular Biochemistry, 2017, 426, 205-213.	1.4	6

#	Article	IF	Citations
253	Autistic symptoms in Greig cephalopolysyndactyly syndrome: a family case report. Journal of Medical Case Reports, 2019, 13, 100.	0.4	6
254	POLG1-Related Epilepsy: Review of Diagnostic and Therapeutic Findings. Brain Sciences, 2020, 10, 768.	1.1	6
255	Sleep problems in attention-deficit/hyperactivity disorder and autism spectrum disorder: Sex differences and parental stress. Psychiatry Research, 2020, 291, 113099.	1.7	6
256	Current role of surgery for tuberous sclerosis complexâ€associated epilepsy. Pediatric Investigation, 2022, 6, 16-22.	0.6	6
257	Diffuse Polymicrogyria Associated With Congenital Hydrocephalus, Craniosynostosis, Severe Mental Retardation, and Minor Facial and Genital Anomalies. Journal of Child Neurology, 2000, 15, 493-495.	0.7	5
258	Convulsive disorder and the genetics of signal transduction; a study of a low molecular weight protein tyrosine phosphatase in a pediatric sample. Neuroscience Letters, 2002, 333, 159-162.	1.0	5
259	Association of Adenosine Deaminase Polymorphism With Mild Mental Retardation. Journal of Child Neurology, 2006, 21, 753-756.	0.7	5
260	Association between D18S474 locus on chromosome 18q12 and idiopathic generalized epilepsy. Brain and Development, 2007, 29, 9-12.	0.6	5
261	Infantile Spasms: Ã Neuro-ophthalmological Study. Developmental Medicine and Child Neurology, 2008, 23, 449-453.	1.1	5
262	Timing and Clinical Characteristics of Topiramate-Induced Psychosis in a Patient With Epilepsy and Tuberous Sclerosis. Clinical Neuropharmacology, 2014, 37, 38-39.	0.2	5
263	Auditory Mismatch Negativity in Youth Affected by Autism Spectrum Disorder With and Without Attenuated Psychosis Syndrome. Frontiers in Psychiatry, 2020, 11, 555340.	1.3	5
264	COVID-19 and social responsiveness: A comparison between children with Sotos syndrome and autism. Psychiatry Research, 2021, 299, 113851.	1.7	5
265	Use of Nutraceutical Ingredient Combinations in the Management of Tension-Type Headaches with or without Sleep Disorders. Nutrients, 2021, 13, 1631.	1.7	5
266	MicroRNAâ€34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis. Neuropathology and Applied Neurobiology, 2021, 47, 796-811.	1.8	5
267	Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders. Antioxidants, 2021, 10, 164.	2.2	5
268	Sleep disorders and neuropsychiatric disorders in a pediatric sample of tuberous sclerosis complex: a questionnaire-based study. Sleep Medicine, 2022, 89, 65-70.	0.8	5
269	Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study. Nutrients, 2022, 14, 852.	1.7	5
270	BAEPs in infantile spasms. Brain and Development, 1989, 11, 347-348.	0.6	4

#	Article	IF	Citations
271	Lack of association between MTHFR C677T and MTHFR A1298C genetic polymorphisms and mental retardation. Nutritional Neuroscience, 2008, 11, 241-242.	1.5	4
272	Reduction in retinal nerve fiber layer thickness in tuberous sclerosis complex. Child's Nervous System, 2015, 31, 857-861.	0.6	4
273	Combined targeted treatment in early onset epilepsy associated with tuberous sclerosis. Epilepsy & Behavior Case Reports, 2016, 5, 13-16.	1.5	4
274	Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period. Journal of Neurodevelopmental Disorders, 2022, 14, 8.	1.5	4
275	Polymicrogyria: A case detected by MRI. Brain and Development, 1989, 11, 257-259.	0.6	3
276	Can we change the course of epilepsy in tuberous sclerosis complex?. Epilepsia, 2010, 51, 1330-1331.	2.6	3
277	Tubers, epileptogenic foci, and epileptogenic networks in tuberous sclerosis. Epilepsia, 2010, 51, 2357-2359.	2.6	3
278	Education in Child Neurology: The Role of the International Child Neurology Association (ICNA). Journal of Child Neurology, 2010, 25, 1444-1449.	0.7	3
279	Autism in tuberous sclerosis: are risk factors identifiable and preventable?. Future Neurology, 2011, 6, 451-454.	0.9	3
280	Effect of Modified-Release Methylphenidate on Cognition in Children with ADHD: Evidence from a Temporal Preparation Task. Timing and Time Perception, 2016, 4, 207-222.	0.4	3
281	Immediate and prolonged-release melatonin in children with neurodevelopmental disabilities. Author reply to Prof. Zisapel. European Journal of Paediatric Neurology, 2017, 21, 420-421.	0.7	3
282	Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions. Journal of Pediatric Neurology, 2017, 15, 134-142.	0.0	3
283	The TOSCA Registry for Tuberous Sclerosisâ€"Lessons Learnt for Future Registry Development in Rare and Complex Diseases. Frontiers in Neurology, 2019, 10, 1182.	1.1	3
284	Evolution of electroencephalogram in infants with tuberous sclerosis complex and neurodevelopmental outcome: a prospective cohort study. Developmental Medicine and Child Neurology, 2022, 64, 495-501.	1.1	3
285	Deletion of the Long Arm of Chromosome 6: Report on a New Case With Intractable Epilepsy. Journal of Child Neurology, 2006, 21, 527-531.	0.7	2
286	Child neurology: role of the International Association. Developmental Medicine and Child Neurology, 2004, 46, 147-147.	1.1	2
287	Introduction. Seminars in Pediatric Neurology, 2015, 22, 205-206.	1.0	2
288	Emotional Lability in Children and Adolescents Affected by Tourette Syndrome. Journal of Pediatric Neurology, 2015, 13, 105-109.	0.0	2

#	Article	IF	Citations
289	Tuberous sclerosisâ€associated epilepsy and intellectual disability: what role does the mammalian target of rapamycin pathway play?. Developmental Medicine and Child Neurology, 2020, 62, 269-269.	1.1	2
290	Neuroimaging and genetic characteristics of malformation of cortical development due to mTOR pathway dysregulation: clues for the epileptogenic lesions and indications for epilepsy surgery. Expert Review of Neurotherapeutics, 2021, 21, 1-13.	1.4	2
291	Lack of association between IDE genetic variability and Down's syndrome. Neuroscience Letters, 2005, 382, 93-95.	1.0	1
292	Tuberous sclerosis complex and hydrosyringomielia: Report of two cases. European Journal of Paediatric Neurology, 2006, 10, 37-40.	0.7	1
293	Lack of Evidence for Association Between D2S124 and D2S111 Polymorphisms of the SCN2A Gene and Idiopathic Generalized Epilepsy With Generalized Tonicâ€"Clonic Seizures. Journal of Child Neurology, 2007, 22, 907-910.	0.7	1
294	Tuberous sclerosis: genes, brain, and behaviour. Developmental Medicine and Child Neurology, 2006, 48, 404-404.	1.1	1
295	Epilepsy in Tuberous Sclerosis Complex. Journal of Pediatric Epilepsy, 2016, 05, 064-069.	0.1	1
296	Can biological components predict short-term evolution in Autism Spectrum Disorders? A proof-of-concept study. Italian Journal of Pediatrics, 2016, 42, 70.	1.0	1
297	Toward targeted treatments in tuberous sclerosis. Expert Opinion on Orphan Drugs, 2016, 4, 243-253.	0.5	1
298	Early Onset Epilepsy Caused by Low-Grade Epilepsy-Associated Tumors and Focal Meningeal Involvement. Brain Sciences, 2020, 10, 752.	1.1	1
299	Long-term use of mTORC1 inhibitors in tuberous sclerosis complex associated neurological aspects. Expert Opinion on Orphan Drugs, 2020, 8, 215-225.	0.5	1
300	TrASDition Training: An online parental training for transition-age youth with autism spectrum disorder. Psychiatry Research, 2021, 300, 113930.	1.7	1
301	Editorial: Tuberous Sclerosis Complex â€“ Diagnosis and Management. Frontiers in Neurology, 2021, 12, 755868.	1.1	1
302	Child neurology: role of the International Association. Developmental Medicine and Child Neurology, 2004, 46, 147.	1.1	1
303	Questionnaire-based assessment of sleep disorders in an adult population of Tuberous Sclerosis Complex. Sleep Medicine, 2022, 92, 81-87.	0.8	1
304	Neuromagnetic 3D localization of interictal epileptogenic foci. Pediatric Neurology, 1994, 11, 131.	1.0	0
305	Vigabatrin in refractory partial seizures due to tuberous sclerosis. Pediatric Neurology, 1994, 11, 150-151.	1.0	0
306	Localization of seizure onset in epilepsy associated with Tuberous Sclerosis. Results of an EEG-MRI fusioning procedure. NeuroImage, 1996, 3, S514.	2.1	0

#	Article	IF	Citations
307	Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment. Journal of Child Neurology, 2004, 19, 318-325.	0.7	0
308	Title is missing!. European Journal of Paediatric Neurology, 2005, 9, 45.	0.7	0
309	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, IX.	1.0	0
310	Educational, cognitive, behavioral and language development issues. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 611-625.	1.0	0
311	Medical treatment in children with central nervous system malformations. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 555-568.	1.0	0
312	Vigabatrin and epilepsy: Further lessons in early childhood. Epilepsia, 2008, 49, 177-178.	2.6	0
313	Epilepsy Associated with Incontinentia Pigmenti. Journal of Pediatric Epilepsy, 2016, 05, 089-096.	0.1	0
314	Advances in Autism Spectrum Disorder. Journal of Pediatric Neurology, 2017, 15, 095-095.	0.0	0
315	New Perspectives in Autism Spectrum Disorder associated with Tuberous Sclerosis. Journal of Pediatric Neurology, 2017, 15, 123-128.	0.0	0
316	Advances in Understanding Autism Spectrum Disorder. Journal of Pediatric Neurology, 2017, 15, 096-098.	0.0	0
317	Decrease in cerebral palsy mortality among children and adolescents in Italy from 1979 to 1993. Developmental Medicine and Child Neurology, 1999, 41, 67-67.	1.1	0
318	First Results of the EPISTOP Study. , 2019, 50, .		0